News | Heart Valve Technology | February 28, 2017

FDA Panel Supports Approval for First TAVR Embolic Protection Device

Claret Medical Sentinel Cerebral Protection System (CPS), FDA, TAVR embolic protection, transcatheter aortic valve replacement (TAVR).

February 28, 2017 — A U.S. Food and Drug Administration (FDA) panel has recommended market clearance for the Claret Medical Sentinel Cerebral Protection System (CPS). The FDA’s Circulatory System Devices Panel reviewed the device last week, which if approved by the FDA would become the first embolic protection system for use with transcatheter aortic valve replacement (TAVR).

The American Association of Neurological Surgeons (AANS) and the Society of NeuroInterventional Surgery (SNIS) endorsed the need for the technology at the panel meeting. The groups were represented at the public hearing by Adnan Siddiqui, M.D., Ph.D., professor of neurological surgery at the University of Buffalo and chief medical officer at the Jacobs Institute. “The Sentinel device has shown its potential, across multiple trials, to filter and remove brain-borne debris safely, with very few vascular complications,” he explained.

The Sentinel CPS is the only device designed to protect the brain by capturing and removing debris dislodged during TAVR that would otherwise enter the cerebral circulation and increase the potential for stroke. A formal vote was not taken as the Sentinel CPS is a medium risk accessory device reviewed as a de novo application.

“The Sentinel device has shown its potential, across multiple trials, to filter and remove brain-borne debris safely, with very few vascular complications,” said Martin Leon, M.D., of Columbia University Medical Center/New York-Presbyterian Hospital, and chairman of the SENTINEL Clinical Steering Committee. “When we see the size and heterogeneity of the material captured, it is reassuring for me as a practicing TAVR implanter to know that it can be removed from the patient’s vasculature before it reaches the brain.“

Read the article “Study Shows Definitive Neuro Benefit to Using TAVR Embolic Protection.”

In the landmark SENTINEL pivotal trial, the primary safety endpoint of MACCE at 30 days was met, with reported MACCE in the protected Sentinel group at 7.3 percent, significantly lower than the pre-specified historical performance goal of 18.3 percent and the rate of 9.9 percent seen in the control arm. The stroke rate for Sentinel-protected patients was 5.6 percent versus 9.1 percent for unprotected patients. Importantly, the observed peri-procedural stroke rate – encompassing 72 hours’ post-procedure — was reduced by 63 percent, from 8.2 percent for unprotected patients to 3 percent for protected patients.

In the trial, device delivery and retrieval were accomplished safely and successfully in 99.6 percent of cases. The Sentinel access site complication rate was only 0.4 percent. The device captured and removed embolic debris in 99 percent of patients in the study, with one in four patients having more than 25 pieces of debris with a size greater than, or equal to, 0.5 millimeters captured in the filters.

A meta-analysis of five randomized controlled clinical trials examining cerebral protection in valve repair and replacement procedures across more than 625 patients was published in the Journal of the American College of Cardiology (JACC) in January. More than 80 percent of the patients (510 subjects) came from three of the five cited studies where Claret Medical’s dual-filter cerebral protection systems were used. These data demonstrate that the use of cerebral protection is associated with a greater than 40 percent lower risk of death or stroke after TAVR. The data corresponded to a rate of one death or stroke potentially being averted for every 22 patients treated with cerebral protection.

“We were extremely pleased with the near unanimous recommendation of the committee based on consideration of the totality of the clinical evidence that we have generated over the past six years. This strong support was based on the excellent safety profile and ability of the Sentinel CPS to reduce cerebral insults,” said Claret Medical President and Chief Executive Officer Azin Parhizgar, Ph.D. “The panel provided valuable feedback that will help define future study success criteria in the field of cerebral protection. We look forward to working collaboratively and diligently with the U.S. FDA in the coming weeks to ensure that we can bring the Sentinel technology to American physicians and their patients.”

The Sentinel CPS is the most-studied device in the field of TAVR cerebral protection, having been systematically evaluated in three randomized controlled trials involving more than 600 patients. More than 3,250 patients worldwide have been protected with the device to-date.

Watch the VIDEO “Defining the Need for TAVR Embolic Protection.”

Read the article “Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR.”

Read the about the late-breaker trial at TCT 2016, “TAVR Embolic Protection Did Not Reduce Emboli Brain Lesions.”
 

For more information: www.claretmedical.com.

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init